Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY HACHIGIAN

Allopathic & Osteopathic Physicians Emergency Medicine

NPI
1558342022
CMS profile
777601
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$108.33

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $108.33 1

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY HACHIGIAN

NPI 1558342022 · CMS profile ID 777601

Allopathic & Osteopathic Physicians / Emergency Medicine

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
GREGORY HACHIGIAN, NPI 1558342022, CMS profile ID 777601, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1558342022?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $108.33 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka Pharmaceutical Development & Commercialization, Inc. $108.3307/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933756527 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $108.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022
Generated from
OP_DTL_GNRL_PGYR2022_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

This record has limited reported data across the program years shown and is not featured in search indexes. The records below are complete; see the methodology for how featured pages are determined.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $281,766.82 21
PY2023 Principal investigator $1,564,117.66 137
PY2022 Principal investigator $4,578,170.79 303
PY2021 Principal investigator $4,478,036.63 220
PY2020 Principal investigator $6,027.12 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

220 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $207.00 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939039
Principal investigator 3 ModernaTX, Inc. $779.63 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939047
Principal investigator 4 ModernaTX, Inc. $5,212.13 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939107
Principal investigator 2 ModernaTX, Inc. $6,000.00 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939115
Principal investigator 3 ModernaTX, Inc. $6,405.00 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939121
Principal investigator 3 ModernaTX, Inc. $8,700.00 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939133
Principal investigator 4 ModernaTX, Inc. $9,375.00 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939137
Principal investigator 3 ModernaTX, Inc. $10,238.76 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939145
Principal investigator 1 ModernaTX, Inc. $10,640.28 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939147
Principal investigator 2 ModernaTX, Inc. $10,950.00 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939153
Principal investigator 4 ModernaTX, Inc. $13,320.00 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939169
Principal investigator 4 ModernaTX, Inc. $14,153.58 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939171
Principal investigator 3 ModernaTX, Inc. $14,755.86 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939177
Principal investigator 3 ModernaTX, Inc. $19,674.48 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939187
Principal investigator 3 ModernaTX, Inc. $22,685.88 12/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939197
Principal investigator 2 ModernaTX, Inc. $103.50 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939033
Principal investigator 2 ModernaTX, Inc. $103.50 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939035
Principal investigator 3 ModernaTX, Inc. $207.00 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939037
Principal investigator 4 ModernaTX, Inc. $207.00 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939041
Principal investigator 2 ModernaTX, Inc. $910.13 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939049
Principal investigator 3 ModernaTX, Inc. $1,093.50 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939051
Principal investigator 2 ModernaTX, Inc. $1,552.50 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939065
Principal investigator 3 ModernaTX, Inc. $1,759.50 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939067
Principal investigator 3 ModernaTX, Inc. $3,105.00 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939083
Principal investigator 4 ModernaTX, Inc. $3,105.00 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939085
Principal investigator 3 ModernaTX, Inc. $3,105.00 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939087
Principal investigator 2 ModernaTX, Inc. $4,511.25 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939095
Principal investigator 2 ModernaTX, Inc. $5,424.75 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939109
Principal investigator 3 ModernaTX, Inc. $5,689.13 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939113
Principal investigator 3 ModernaTX, Inc. $6,331.50 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939119
Principal investigator 4 ModernaTX, Inc. $8,026.88 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939129
Principal investigator 4 ModernaTX, Inc. $8,398.13 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939131
Principal investigator 3 ModernaTX, Inc. $10,839.38 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939151
Principal investigator 1 ModernaTX, Inc. $12,702.38 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939163
Principal investigator 4 ModernaTX, Inc. $12,948.75 12/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939167
Principal investigator 2 ModernaTX, Inc. $103.50 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939031
Principal investigator 1 ModernaTX, Inc. $1,407.38 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939061
Principal investigator 3 ModernaTX, Inc. $2,255.63 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939071
Principal investigator 1 ModernaTX, Inc. $2,523.38 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939077
Principal investigator 2 ModernaTX, Inc. $2,958.75 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939081
Principal investigator 2 ModernaTX, Inc. $3,201.75 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939089
Principal investigator 4 ModernaTX, Inc. $3,661.88 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939091
Principal investigator 2 ModernaTX, Inc. $3,868.88 12/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939093
Principal investigator 1 ModernaTX, Inc. $10,693.13 12/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939149
Principal investigator 2 ModernaTX, Inc. $14,829.75 12/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939179
Principal investigator 1 ModernaTX, Inc. $3,093.35 11/26/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939015
Principal investigator 2 ModernaTX, Inc. $3,607.50 11/26/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939017
Principal investigator 3 ModernaTX, Inc. $1,153.13 11/26/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939057
Principal investigator 3 ModernaTX, Inc. $2,869.88 11/26/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939079
Principal investigator 3 ModernaTX, Inc. $5,564.25 11/26/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939111
Principal investigator 1 ModernaTX, Inc. $750.00 11/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 860939211
Principal investigator 4 ModernaTX, Inc. $1,500.00 11/10/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939063
Principal investigator 1 ModernaTX, Inc. $2,025.32 11/10/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 860939213
Principal investigator 3 ModernaTX, Inc. $33,155.20 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939019
Principal investigator 4 ModernaTX, Inc. $78,933.40 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939021
Principal investigator 1 ModernaTX, Inc. $160,093.70 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939023
Principal investigator 3 ModernaTX, Inc. $178,891.70 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939025
Principal investigator 1 ModernaTX, Inc. $182,366.60 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939027
Principal investigator 3 ModernaTX, Inc. $261,937.00 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants No dispute reported 06/30/2026 860939029
Principal investigator 2 ModernaTX, Inc. $1,153.13 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939055
Principal investigator 4 ModernaTX, Inc. $4,657.50 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939097
Principal investigator 1 ModernaTX, Inc. $4,819.50 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939101
Principal investigator 2 ModernaTX, Inc. $5,175.00 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939103
Principal investigator 1 ModernaTX, Inc. $5,175.00 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939105
Principal investigator 1 ModernaTX, Inc. $7,292.25 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939127
Principal investigator 2 ModernaTX, Inc. $9,876.87 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939139
Principal investigator 2 ModernaTX, Inc. $10,004.63 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939143
Principal investigator 1 ModernaTX, Inc. $11,503.13 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939155
Principal investigator 4 ModernaTX, Inc. $12,830.00 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939165
Principal investigator 1 ModernaTX, Inc. $14,604.75 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939175
Principal investigator 2 ModernaTX, Inc. $20,311.88 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939191
Principal investigator 1 ModernaTX, Inc. $20,811.25 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939193
Principal investigator 3 ModernaTX, Inc. $27,525.38 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939203
Principal investigator 3 ModernaTX, Inc. $28,864.13 11/05/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939207
Principal investigator 3 ModernaTX, Inc. $6,195.00 11/03/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939117
Principal investigator 2 ModernaTX, Inc. $7,005.00 11/03/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939125
Principal investigator 1 ModernaTX, Inc. $11,543.70 11/03/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939159
Principal investigator 4 ModernaTX, Inc. $12,547.50 11/03/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939161
Principal investigator 4 ModernaTX, Inc. $373.50 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939043
Principal investigator 1 ModernaTX, Inc. $779.63 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939045
Principal investigator 2 ModernaTX, Inc. $1,153.13 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939053
Principal investigator 3 ModernaTX, Inc. $2,306.25 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939073
Principal investigator 4 ModernaTX, Inc. $2,506.38 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939075
Principal investigator 2 ModernaTX, Inc. $6,938.00 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939123
Principal investigator 1 ModernaTX, Inc. $9,299.25 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939135
Principal investigator 3 ModernaTX, Inc. $9,990.00 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939141
Principal investigator 1 ModernaTX, Inc. $11,520.00 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939157
Principal investigator 2 ModernaTX, Inc. $14,175.00 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939173
Principal investigator 2 ModernaTX, Inc. $15,580.09 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939181
Principal investigator 1 ModernaTX, Inc. $17,610.00 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939183
Principal investigator 1 ModernaTX, Inc. $18,068.40 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939185
Principal investigator 1 ModernaTX, Inc. $19,975.62 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939189
Principal investigator 3 ModernaTX, Inc. $21,309.75 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939195
Principal investigator 3 ModernaTX, Inc. $24,098.63 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939199
Principal investigator 4 ModernaTX, Inc. $27,504.12 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939201
Principal investigator 4 ModernaTX, Inc. $28,168.88 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939205
Principal investigator 3 ModernaTX, Inc. $32,924.64 10/22/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939209
Principal investigator 2 ModernaTX, Inc. $1,932.75 10/13/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939069
Principal investigator 1 ModernaTX, Inc. $2,829.38 10/13/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Lyophilized Cytomegalovirus Vaccine mRNA-1647 in Healthy Adults No dispute reported 06/30/2026 860939215
Principal investigator 1 ModernaTX, Inc. $1,256.63 10/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939059
Principal investigator 1 ModernaTX, Inc. $4,687.50 10/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939099
Principal investigator 4 ModernaTX, Inc. $13,090.50 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939295
Principal investigator 1 ModernaTX, Inc. $774.75 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939297
Principal investigator 1 ModernaTX, Inc. $401.25 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939299
Principal investigator 3 ModernaTX, Inc. $133.75 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939301
Principal investigator 1 ModernaTX, Inc. $12,322.13 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939303
Principal investigator 1 ModernaTX, Inc. $2,084.63 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939305
Principal investigator 4 ModernaTX, Inc. $14,811.75 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939307
Principal investigator 2 ModernaTX, Inc. $25,482.75 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939309
Principal investigator 4 ModernaTX, Inc. $1,720.00 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939391
Principal investigator 1 ModernaTX, Inc. $3,325.50 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939393
Principal investigator 2 ModernaTX, Inc. $1,443.38 09/24/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939395
Principal investigator 4 ModernaTX, Inc. $3,500.00 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939293
Principal investigator 2 ModernaTX, Inc. $4,347.00 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939605
Principal investigator 2 ModernaTX, Inc. $310.50 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939607
Principal investigator 1 ModernaTX, Inc. $401.25 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939609
Principal investigator 1 ModernaTX, Inc. $802.50 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939611
Principal investigator 3 ModernaTX, Inc. $267.50 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939613
Principal investigator 1 ModernaTX, Inc. $198.05 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939615
Principal investigator 2 ModernaTX, Inc. $8,790.00 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939617
Principal investigator 1 ModernaTX, Inc. $18,068.40 09/17/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939619
Principal investigator 1 ModernaTX, Inc. $19,635.00 09/15/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939387
Principal investigator 2 ModernaTX, Inc. $32,523.12 09/15/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939389
Principal investigator 2 ModernaTX, Inc. $4,000.00 09/15/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939601
Principal investigator 3 ModernaTX, Inc. $3,500.00 09/15/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939603
Principal investigator 3 ModernaTX, Inc. $1,200.00 09/10/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939397
Principal investigator 3 ModernaTX, Inc. $8,250.00 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939283
Principal investigator 3 ModernaTX, Inc. $14,115.00 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939285
Principal investigator 1 ModernaTX, Inc. $16,125.00 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939287
Principal investigator 2 ModernaTX, Inc. $75,900.00 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939289
Principal investigator 4 ModernaTX, Inc. $26,801.46 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939291
Principal investigator 2 ModernaTX, Inc. $8,250.00 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939381
Principal investigator 3 ModernaTX, Inc. $4,000.00 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939383
Principal investigator 3 ModernaTX, Inc. $27,825.00 09/08/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939385
Principal investigator 4 ModernaTX, Inc. $8,065.25 09/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939597
Principal investigator 2 ModernaTX, Inc. $1,700.00 09/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939599
Principal investigator 4 ModernaTX, Inc. $868.50 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939269
Principal investigator 3 ModernaTX, Inc. $151,053.75 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939271
Principal investigator 2 ModernaTX, Inc. $75,540.38 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939273
Principal investigator 2 ModernaTX, Inc. $6,864.75 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939275
Principal investigator 2 ModernaTX, Inc. $165.38 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939277
Principal investigator 3 ModernaTX, Inc. $83,117.25 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939279
Principal investigator 4 ModernaTX, Inc. $36,417.38 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939281
Principal investigator 4 ModernaTX, Inc. $1,363.63 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939367
Principal investigator 3 ModernaTX, Inc. $2,679.75 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939369
Principal investigator 1 ModernaTX, Inc. $373.50 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939371
Principal investigator 1 ModernaTX, Inc. $165.38 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939373
Principal investigator 2 ModernaTX, Inc. $107.00 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939375
Principal investigator 4 ModernaTX, Inc. $103.50 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939377
Principal investigator 1 ModernaTX, Inc. $2,018.38 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939379
Principal investigator 2 ModernaTX, Inc. $18,971.82 08/27/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939595
Principal investigator 4 ModernaTX, Inc. $19,136.00 08/25/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939443
Principal investigator 2 ModernaTX, Inc. $1,473.75 08/25/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939445
Principal investigator 3 ModernaTX, Inc. $707.00 08/25/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939447
Principal investigator 3 ModernaTX, Inc. $1,656.00 08/25/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939449
Principal investigator 2 ModernaTX, Inc. $8,797.50 08/25/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939451
Principal investigator 2 ModernaTX, Inc. $8,191.13 08/25/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939453
Principal investigator 4 ModernaTX, Inc. $5,870.25 08/25/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939455
Principal investigator 4 ModernaTX, Inc. $739.13 08/20/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939365
Principal investigator 1 ModernaTX, Inc. $27,002.00 08/18/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939267
Principal investigator 3 ModernaTX, Inc. $10,635.00 08/18/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939437
Principal investigator 3 ModernaTX, Inc. $18,369.54 08/18/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939439
Principal investigator 2 ModernaTX, Inc. $20,000.00 08/18/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939441
Principal investigator 1 ModernaTX, Inc. $26,901.84 08/11/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939263
Principal investigator 1 ModernaTX, Inc. $25,195.38 08/11/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939265
Principal investigator 2 ModernaTX, Inc. $33,225.78 08/11/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939361
Principal investigator 3 ModernaTX, Inc. $18,780.00 08/11/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939363
Principal investigator 2 ModernaTX, Inc. $15,975.00 08/04/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939261
Principal investigator 1 ModernaTX, Inc. $165.38 07/28/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939259
Principal investigator 2 ModernaTX, Inc. $12,450.00 07/28/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939435
Principal investigator 2 ModernaTX, Inc. $33,627.30 07/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939357
Principal investigator 4 ModernaTX, Inc. $32,523.12 07/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939359
Principal investigator 1 ModernaTX, Inc. $21,121.88 07/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939425
Principal investigator 3 ModernaTX, Inc. $27,651.38 07/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939427
Principal investigator 3 ModernaTX, Inc. $52,384.50 07/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939429
Principal investigator 3 ModernaTX, Inc. $89,093.25 07/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939431
Principal investigator 3 ModernaTX, Inc. $13,425.75 07/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939433
Principal investigator 1 ModernaTX, Inc. $10,184.63 07/21/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939419
Principal investigator 4 ModernaTX, Inc. $13,883.63 07/21/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939421
Principal investigator 3 ModernaTX, Inc. $2,898.00 07/21/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939423
Principal investigator 4 ModernaTX, Inc. $19,605.00 07/16/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939355
Principal investigator 3 ModernaTX, Inc. $9,225.00 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939333
Principal investigator 4 ModernaTX, Inc. $1,131.75 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939335
Principal investigator 4 ModernaTX, Inc. $13,177.13 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939337
Principal investigator 4 ModernaTX, Inc. $4,957.88 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939339
Principal investigator 4 ModernaTX, Inc. $29,295.00 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939341
Principal investigator 2 ModernaTX, Inc. $10,029.38 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939343
Principal investigator 4 ModernaTX, Inc. $2,815.88 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939345
Principal investigator 4 ModernaTX, Inc. $65,936.25 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939347
Principal investigator 4 ModernaTX, Inc. $6,775.88 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939349
Principal investigator 4 ModernaTX, Inc. $56,514.38 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939351
Principal investigator 1 ModernaTX, Inc. $1,153.13 07/14/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939353
Principal investigator 3 ModernaTX, Inc. $89,502.75 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939399
Principal investigator 3 ModernaTX, Inc. $10,890.00 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939401
Principal investigator 4 ModernaTX, Inc. $19,272.96 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939403
Principal investigator 1 ModernaTX, Inc. $1,737.00 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939405
Principal investigator 1 ModernaTX, Inc. $11,445.75 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939407
Principal investigator 2 ModernaTX, Inc. $6,385.50 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939409
Principal investigator 4 ModernaTX, Inc. $82,924.88 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939411
Principal investigator 3 ModernaTX, Inc. $23,596.88 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939413
Principal investigator 4 ModernaTX, Inc. $56,073.38 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939415
Principal investigator 1 ModernaTX, Inc. $20,491.25 07/07/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939417
Principal investigator 2 ModernaTX, Inc. $31,179.38 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939313
Principal investigator 3 ModernaTX, Inc. $4,342.50 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939315
Principal investigator 3 ModernaTX, Inc. $89,033.63 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939317
Principal investigator 4 ModernaTX, Inc. $43,574.63 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939319
Principal investigator 3 ModernaTX, Inc. $44,613.00 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939321
Principal investigator 3 ModernaTX, Inc. $74,248.88 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939323
Principal investigator 1 ModernaTX, Inc. $74,515.50 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939325
Principal investigator 2 ModernaTX, Inc. $99,799.88 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939327
Principal investigator 4 ModernaTX, Inc. $131,967.00 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939329
Principal investigator 4 ModernaTX, Inc. $7,464.38 07/01/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939331
Principal investigator 3 ModernaTX, Inc. $3,474.00 06/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939247
Principal investigator 1 ModernaTX, Inc. $43,627.50 06/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939249
Principal investigator 1 ModernaTX, Inc. $72,013.50 06/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939251
Principal investigator 2 ModernaTX, Inc. $81,348.75 06/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939253
Principal investigator 4 ModernaTX, Inc. $91,005.75 06/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939255
Principal investigator 2 ModernaTX, Inc. $6,406.88 06/23/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939257
Principal investigator 2 ModernaTX, Inc. $17,460.00 06/18/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939245
Principal investigator 2 ModernaTX, Inc. $21,435.00 06/18/2021 Non-covered Recipient Entity
LSB RESEARCH GROUP LLC
A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older No dispute reported 06/30/2026 860939311